This afternoon we watched Apellis Pharmaceuticals rise 14.3% to a price of $61.58 per share. The mid-cap None company is now trading -13.5% below its average target price of $71.19. Analysts have set target prices ranging from $44.0 to $95.0 per share for Apellis Pharmaceuticals, and have given the stock an average rating of buy.
Apellis Pharmaceuticals has an elevated short interest of 15.8%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 8.36. Since 13.63% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. 96.8% of Apellis Pharmaceuticals shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Apellis Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Wellington Management Group, LLP | 13% | 15,167,044 | $933,986,597 |
| 2023-09-30 | Avoro Capital Advisors LLC | 9% | 11,111,111 | $684,222,235 |
| 2023-09-30 | EcoR1 Capital, LLC | 9% | 10,899,859 | $671,213,337 |
| 2023-09-30 | Vanguard Group Inc | 8% | 9,469,977 | $583,161,201 |
| 2023-09-30 | T. Rowe Price Investment Management, Inc. | 6% | 6,519,471 | $401,469,036 |
| 2023-09-30 | Blackrock Inc. | 4% | 5,272,746 | $324,695,708 |
| 2023-09-30 | Jennison Associates LLC | 3% | 3,542,209 | $218,129,236 |
| 2023-09-30 | State Street Corporation | 3% | 3,238,114 | $199,403,066 |
| 2023-09-30 | Octagon Capital Advisors LP | 3% | 3,130,000 | $192,745,405 |
| 2023-09-30 | FMR, LLC | 2% | 2,259,766 | $139,156,394 |
For these reasons, we consider that the Apellis Pharmaceuticals is the subject of None.
